ARS Pharmaceuticals Inc.
07/07/2026 | Press release | Distributed by Public on 07/07/2026 14:39
Management Change/Compensation (Form 8-K)
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On July 7, 2026, the Board of Directors (the "Board") of ARS Pharmaceuticals, Inc. (the "Company") appointed the Company's current President Donn Casale as the Company's Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity. Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company's 2029 annual meeting of stockholders. Mr. Lowenthal was notified on July 6, 2026 that his employment was being terminated without cause, effective immediately.
Mr. Casale's biographical information is contained in the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 13, 2026, and is incorporated by reference herein.
ARS Pharmaceuticals Inc. published this content on July 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 07, 2026 at 20:39 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]